ProShare Advisors LLC Has $26.53 Million Stock Position in Pfizer Inc. $PFE

ProShare Advisors LLC raised its position in Pfizer Inc. (NYSE:PFE) by 10.6% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,094,571 shares of the biopharmaceutical company’s stock after buying an additional 104,687 shares during the period. ProShare Advisors LLC’s holdings in Pfizer were worth $26,532,000 as of its most recent filing with the SEC.

Several other large investors have also recently modified their holdings of the business. Westbourne Investments Inc. bought a new position in Pfizer during the 1st quarter valued at approximately $2,411,000. Bourne Lent Asset Management Inc. grew its position in Pfizer by 90.8% during the 2nd quarter. Bourne Lent Asset Management Inc. now owns 38,255 shares of the biopharmaceutical company’s stock valued at $927,000 after purchasing an additional 18,200 shares during the last quarter. Strs Ohio bought a new stake in shares of Pfizer during the first quarter valued at approximately $49,968,000. IFM Investors Pty Ltd raised its stake in shares of Pfizer by 3.8% in the second quarter. IFM Investors Pty Ltd now owns 1,127,143 shares of the biopharmaceutical company’s stock worth $27,322,000 after purchasing an additional 41,263 shares during the last quarter. Finally, Intrua Financial LLC grew its position in Pfizer by 17.4% in the 1st quarter. Intrua Financial LLC now owns 78,392 shares of the biopharmaceutical company’s stock worth $1,986,000 after purchasing an additional 11,643 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on PFE. UBS Group reissued a “neutral” rating and set a $28.00 price target on shares of Pfizer in a report on Wednesday, October 1st. Sanford C. Bernstein restated a “market perform” rating and set a $30.00 price target on shares of Pfizer in a report on Friday, October 31st. Morgan Stanley reduced their price objective on Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a research note on Friday, October 10th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday, October 8th. Finally, Bank of America upped their target price on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research note on Friday, October 3rd. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $28.18.

Pfizer Price Performance

NYSE:PFE opened at $25.49 on Wednesday. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $27.69. The stock has a market capitalization of $144.93 billion, a PE ratio of 13.56, a price-to-earnings-growth ratio of 0.81 and a beta of 0.54. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The stock’s 50-day moving average price is $24.75 and its 200-day moving average price is $24.41.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, beating the consensus estimate of $0.79 by $0.08. The firm had revenue of $16.65 billion during the quarter, compared to the consensus estimate of $16.94 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, equities analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be issued a $0.43 dividend. The ex-dividend date is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a yield of 6.7%. Pfizer’s dividend payout ratio (DPR) is 100.00%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.